It’s the size of a desktop.
Doctors around the world may soon have access to a new tool that could better predict whether individual cancer patients will benefit from immune checkpoint inhibitors—a type of immunotherapy—using only routine blood tests and clinical data.
The artificial intelligence–based model, dubbed SCORPIO, was developed by a team of researchers from Memorial Sloan Kettering Cancer Center (MSK) and the Tisch Cancer Institute at Mount Sinai.
The model is not only cheaper and more accessible, it’s significantly better at predicting outcomes than the two current biomarkers approved by the U.S. Food and Drug Administration (FDA), according to findings published in Nature Medicine.
OpenAI’s CEO Sam Altman reveals the company already has its eyes set on achieving Artificial Superintelligence (ASI). Watch to find out more!
*Correction: Joshua Achiam is not the Head of Alignment he is the Head of Mission Alignment. He says \.
Meta has appointed three new members to its board of directors, the company announced Monday: UFC president and CEO Dana White, European investment company Exor CEO John Elkann, and tech investor and entrepreneur Charlie Songhurst.
In a press release, Meta CEO Mark Zuckerberg said that White, Elkann, and Songhurst “will add a depth of expertise and perspective” that’ll help Meta “tackle the massive opportunities ahead with AI, wearables, and the future of human connection.”
White was named CEO of UFC in 2023, after the organization merged with WWE to form a new public company, TKO Group Holdings. He’s responsible for the overall strategic direction of UFC’s global business, including its live events series.
PairNet: Training with Observed Pairs to Estimate Individual Treatment Effect. Predicting How Treatments Affect Individuals: A New Approach with PairN
Posted in futurism | Leave a Comment on PairNet: Training with Observed Pairs to Estimate Individual Treatment Effect. Predicting How Treatments Affect Individuals: A New Approach with PairN
Predicting How Treatments Affect Individuals: A New Approach with PairNet.
Speakers: Cecile Tamura, Lokesh N, Riju Pahwa
BioViva focuses on translating this research into therapies.
In the search to extend human lifespan and address age-related diseases, telomerase reverse transcriptase (TERT) stands out as a promising focus of research. This enzyme, known for its role in maintaining telomeres—the protective caps at the ends of chromosomes—offers potential pathways to combat ageing at a cellular level. BioViva, under the leadership of CEO Liz Parrish, is working to transform telomerase-based scientific breakthroughs into tangible therapies aimed at enhancing health and longevity.
The race to replace human workers continues in Big Tech, but not everyone is convinced it will happen so soon.
12 billion-year-old galaxies were 90% surrounded by glowing gas, igniting intense star formation.